XLO

Xilio Development Inc
CAPPED RATING

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Xilio Development Inc (XLO) is rated C (2.5/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Growth (A+); its weakest is Profitability (D-). The rating has held at C for 56 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C
Value
C+
Factor Score 2.6 / 5.0
Growth
A+
Factor Score 5.0 / 5.0
Profitability
D-
Factor Score 1.0 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
D+
Factor Score 1.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA N/A
Rev Growth YoY 243.0%
Gross Margin 0.0%
Price Return 3M 9.4%
Price Return 12M -5.9%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 7.7
ROE -224.1%

Historical Factor Score Progression

Held C for 56 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-07-29 C+ (2.6) A+ (5.0) D- (1.0) C (2.4) D+ (1.5) C (2.5)
2025-06-30 C+ (2.6) A+ (5.0) D- (1.0) C (2.4) D+ (1.5) C (2.5)
2025-03-31 C+ (2.7) C+ (2.5) D- (1.1) C (2.4) D+ (1.5) C- (2.0)
2024-12-31 C+ (2.6) C+ (2.5) D- (1.0) C (2.3) D (1.5) C- (2.0)
2024-09-30 C+ (2.6) C+ (2.5) D- (1.0) C (2.3) D+ (1.5) C- (2.0)
Page 1 of 2